Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.57 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | HTR1D | P28221 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | HTR1F | P30939 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261059 | 0.83 | HTR6 (0.67) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL13120225 | 0.79 | HTR6 (0.68) | HTR6CYP3A4CYP2D6BCHE | |
| SCHEMBL13378917 | 0.79 | HTR6 (0.66) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL4029770 | 0.79 | HTR6 (0.72) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL7449413 | 0.78 | HTR6 (0.71) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL20742940 | 0.77 | HTR6 (0.53) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL13422056 | 0.77 | HTR6 (0.57) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL29783668 | 0.77 | HTR6 (0.53) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL28781693 | 0.77 | HTR6 (0.59) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL7441975 | 0.76 | HTR6 (0.62) | HTR6HTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| CN-101014345-A | Tricyclic anilide spirolactam cgrp receptor antagonists | MERCK & CO INC (US) | 2007-08-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | HTR6 231/4885HTR1A 164/4885HTR1D 139/4885 |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | HTR6 278/4885HTR1A 81/4885HTR1D 67/4885 |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | C1R, CALCB, MRGPRX2 | HTR6 863/4885HTR1A 306/4885HTR1D 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.